|
US11566082B2
(en)
|
2014-11-17 |
2023-01-31 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
|
WO2017194592A1
(en)
|
2016-05-11 |
2017-11-16 |
Ge Healthcare Bioprocess R&D Ab |
Method of storing a separation matrix
|
|
US10730908B2
(en)
|
2016-05-11 |
2020-08-04 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
|
JP7031934B2
(ja)
|
2016-05-11 |
2022-03-08 |
サイティバ・バイオプロセス・アールアンドディ・アクチボラグ |
分離マトリックス
|
|
EP3455241B1
(en)
|
2016-05-11 |
2022-02-23 |
Cytiva BioProcess R&D AB |
Method of cleaning and/or sanitizing a separation matrix
|
|
JP7122974B2
(ja)
|
2016-05-11 |
2022-08-22 |
サイティバ・バイオプロセス・アールアンドディ・アクチボラグ |
変異免疫グロブリン結合ポリペプチド
|
|
US10703774B2
(en)
|
2016-09-30 |
2020-07-07 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
|
US10654887B2
(en)
|
2016-05-11 |
2020-05-19 |
Ge Healthcare Bio-Process R&D Ab |
Separation matrix
|
|
US12448411B2
(en)
|
2016-09-30 |
2025-10-21 |
Cytiva Bioprocess R&D Ab |
Separation method
|
|
EP3824906A1
(en)
|
2016-12-21 |
2021-05-26 |
Amgen Inc. |
Anti-tnf alpha antibody formulations
|
|
US10722589B2
(en)
|
2017-04-03 |
2020-07-28 |
Covagen Ag |
FGFR3 binding molecules
|
|
US20190153096A1
(en)
|
2017-10-02 |
2019-05-23 |
Covagen Ag |
Cd3/cd33 bispecific binding molecules
|
|
US20190100587A1
(en)
|
2017-10-02 |
2019-04-04 |
Covagen Ag |
IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
|
|
AU2019353367A1
(en)
*
|
2018-10-02 |
2021-02-18 |
Mitsubishi Tanabe Pharma Corporation |
Bi-specific binding agents targeting syndecan-1 and fibroblast growth factor receptor
|
|
KR20210109520A
(ko)
|
2018-12-28 |
2021-09-06 |
쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 |
항체 및 이의 용도
|
|
EP3957652A4
(en)
|
2019-04-16 |
2023-06-21 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Anti-fxi/fxia antibody and use thereof
|
|
CN114206931B
(zh)
|
2019-09-30 |
2024-06-04 |
四川科伦博泰生物医药股份有限公司 |
抗pd-1抗体及其用途
|
|
EP4047019A4
(en)
|
2019-12-13 |
2023-11-15 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Anti-tslp antibody and uses thereof
|
|
CR20220580A
(es)
|
2020-05-15 |
2023-04-11 |
Sichuan Kelun Biotech Biopharmaceutical Co Ltd |
Conjugado anticuerpo-fármaco, método de preparación del mismo y uso del mismo
|
|
KR20230098221A
(ko)
|
2020-10-26 |
2023-07-03 |
아케소 바이오파마, 인크. |
항-tigit 항체, 약학 조성물 및 이의 용도
|
|
TW202604963A
(zh)
|
2020-12-31 |
2026-02-01 |
中國商諾納生物（蘇州）有限公司 |
人lifr抗原結合蛋白及其製備方法和應用
|
|
WO2022157493A1
(en)
|
2021-01-21 |
2022-07-28 |
Eusa Pharma (Uk) Limited |
Method for treating il-6 associated histiocytic and lymphoproliferative disorders
|
|
WO2022188652A1
(zh)
|
2021-03-09 |
2022-09-15 |
四川科伦博泰生物医药股份有限公司 |
Ror1结合蛋白及其用途
|
|
US20240352153A1
(en)
|
2021-07-23 |
2024-10-24 |
Akeso Biopharma, Inc |
Pharmaceutical composition and use
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
CN114181310B
(zh)
|
2022-02-14 |
2022-07-05 |
中山康方生物医药有限公司 |
抗tigit抗体、其药物组合物及用途
|
|
CN114853890B
(zh)
|
2022-03-16 |
2023-04-28 |
沈阳三生制药有限责任公司 |
一种prlr抗原结合蛋白及其制备方法和应用
|
|
CN116925222A
(zh)
|
2022-04-02 |
2023-10-24 |
普米斯生物技术(珠海)有限公司 |
抗pvrig抗体、其药物组合物及用途
|
|
CN116925233A
(zh)
|
2022-04-02 |
2023-10-24 |
普米斯生物技术(珠海)有限公司 |
抗tigit-抗pvrig双特异性抗体、其药物组合物及用途
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
WO2024228389A1
(ja)
*
|
2023-05-02 |
2024-11-07 |
田辺三菱製薬株式会社 |
対象における二重特異性融合ポリペプチドの有効性を予測するための方法
|
|
CN122138981A
(zh)
*
|
2023-09-11 |
2026-06-02 |
豪夫迈·罗氏有限公司 |
靶向血管生成因子和炎性因子的多特异性融合蛋白
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
KR20250091367A
(ko)
|
2023-12-13 |
2025-06-23 |
주식회사 노드큐어 |
개 pdl-1 항체 및 이의 용도
|
|
WO2025224095A1
(en)
|
2024-04-22 |
2025-10-30 |
Recordati Netherlands Bv |
Use of inhibitors of il-6 or il-6r for treating graft versus host disease in a subject
|
|
PL448731A1
(pl)
*
|
2024-05-31 |
2025-12-01 |
Celon Pharma Spółka Akcyjna |
Przeciwciała bispecyficzne anty–IL-17A i anty-IL-6 oraz ich zastosowanie w terapii, zwłaszcza w leczeniu chorób immunologicznych
|
|
WO2026102093A1
(en)
|
2024-11-07 |
2026-05-15 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|